Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson's disease: a pilot study
Jazyk angličtina Země Rakousko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- biologické markery mozkomíšní mok MeSH
- chromogranin A mozkomíšní mok MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- Parkinsonova nemoc mozkomíšní mok diagnóza MeSH
- pilotní projekty MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- chromogranin A MeSH
Chromogranin A (CgA) levels in cerebrospinal fluid (CSF) have been reported to be significantly reduced in the later stages of Parkinson's disease (PD). There are only limited data regarding its levels in the early stages, so its significance as a potential biomarker in the diagnosis of PD cannot be established. The aim of our study was to establish the level of CgA in a cohort of treatment-naïve patients with early stage PD. Ten patients (4 males, 6 females) and 10 gender- and age-matched controls were examined for CgA levels in the CSF. Control subjects were patients with low-back pain or tension-type headache. The mean CSF CgA level in PD patients was 74.8 (41.9-123.8) μg/l; in the control group it was 143.9 (116-181.3) μg/l. Statistical analysis showed a difference at the significance level P ≤ 0.05. Our pilot study shows that CSF CgA levels are reduced in the early stages of PD. CgA could therefore be a potential biomarker helpful in the diagnosis of PD.
Zobrazit více v PubMed
J Neural Transm (Vienna). 2011 May;118(5):727-35 PubMed
Neuroscience. 1993 Oct;56(4):999-1007 PubMed
N Engl J Med. 2003 Mar 20;348(12):1134-49 PubMed
J Mol Neurosci. 2012 Oct;48(2):347-56 PubMed
J Neural Transm (Vienna). 1998;105(1):39-51 PubMed
J Clin Invest. 2005 Jul;115(7):1942-52 PubMed
Brain Res. 1994 Jan 21;634(2):339-44 PubMed
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52 PubMed
FEBS Lett. 1990 Apr 24;263(2):337-9 PubMed
Neuroscience. 2010 Sep 29;170(1):289-97 PubMed
Regul Pept. 2010 Nov 30;165(1):5-11 PubMed
J Clin Invest. 2005 Jul;115(7):1711-3 PubMed
Dementia. 1995 Nov-Dec;6(6):306-11 PubMed
Regul Pept. 2009 Jan 8;152(1-3):13-21 PubMed
Biochem J. 1965 Dec;97(3):40C-41C PubMed
Biol Psychiatry. 1996 Jun 1;39(11):911-8 PubMed
Mov Disord. 2011 Feb 15;26(3):436-41 PubMed
Brain Res. 1984 Dec;320(2-3):193-230 PubMed
Hypertension. 1995 Jul;26(1):213-20 PubMed
Adv Exp Med Biol. 2000;482:377-88 PubMed
Neurosci Lett. 1994 Mar 28;170(1):13-6 PubMed
Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy
